CURETECH LTD.
๐ง๐ฉBangladesh
- Country
- ๐ง๐ฉBangladesh
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://curetechbio.com
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT00966251
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Center, Jerusalem, Israel
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT00962936
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Center, Jerusalem, Israel
CT-011 MAb in DLBCL Patients Following ASCT
Phase 2
Completed
- Conditions
- Primary Mediastinal Large B-Cell LymphomaLymphoma, Large Cell, DiffuseLymphoma, Mixed Cell, Diffuse
- Interventions
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT00532259
- Locations
- ๐บ๐ธ
Rush University Medical Center, Chicago, Illinois, United States
๐บ๐ธThe University of Chicago, Chicago, Illinois, United States
๐ฎ๐ณJaslok Hospital and Research Centre, Mumbai, Maharashtra, India
ยฉ Copyright 2025. All Rights Reserved by MedPath